SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
International experience in controlling pharmaceutical expenditure: influencing patients and providers and regulating industry – a systematic review
16 references·0 citing·41 second hop
International experience in controlling pharmaceutical expenditure: influencing patients and providers and regulating industry – a systematic review (2014)International experience in controlling p…Effects of health savings account-eligible plans on utilization and expenditures. (2011)Effects of health savings acc…Cochrane Database of Systematic Reviews (2011)Cochrane Database of Systemat…Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies (2006)Pharmaceutical policies: effe…Impact of Alternative Interventions on Changes in Generic Dispensing Rates (2006)Impact of Alternative Interve…Impact of a generic substitution reform on patients’ and society's expenditure for pharmaceuticals (2006)Impact of a generic substitut…Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality (2005)Regulating Pharmaceuticals in…Effects of Prescription Drug User Fees on Drug and Health Services Use and on Health Status in Vulnerable Populations: A Systematic Review of the Evidence (2004)Effects of Prescription Drug …A prospective multicenter study of the effect of patient education on acceptability of generic prescribing in general practice (2003)A prospective multicenter stu…When Is It Cost-effective to Change the Behavior of Health Professionals? (2001)When Is It Cost-effective to …Pharmaceutical Policies in OECD Countries: Reconciling Social and Industrial Goals (2000)Pharmaceutical Policies in OE…Pharmaceutical Policies in OECD Countries (2000)Pharmaceutical Policies in OE…Lessons from international experience in controlling pharmaceutical expenditure. I: influencing patients (1996)Lessons from international ex…Lessons from international experience in controlling pharmaceutical expenditure III: regulating industry: Table 1 (1996)Lessons from international ex…Fortnightly Review: Lessons from international experience in controlling pharmaceutical expenditure II: influencing doctors (1996)Fortnightly Review: Lessons f…Effects of Medicaid Drug-Payment Limits on Admission to Hospitals and Nursing Homes (1991)Effects of Medicaid Drug-Paym…Charging for health care: Evidence on the utilisation of NHS prescribed drugs (1991)Charging for health care: Evi…INTERRUPTED TIME SERIES DESIGNS IN HEALTH TECHNOLOGY ASSESSMENT: LESSONS FROM TWO SYSTEMATIC REVIEWS OF BEHAVIOR CHANGE STRATEGIES (2003)Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration (2008)Pharmaceutical policies: effects of cap and co-payment on rational drug use (2008)GRADE guidelines: 3. Rating the quality of evidence (2011)Cost-Containment Policies in Public Pharmaceutical Spending in the EU (2012)Policies to promote use of generic medicines in low and middle income countries: A review of published literature, 2000–2010 (2012)Payment Restrictions for Prescription Drugs under Medicaid (1987)Adverse Events Associated With Prescription Drug Cost-Sharing Among Poor and Elderly Persons (2001)Regulating pharmaceuticals in Europe : striving for efficiency, equity and quality (2004)What impact do prescription drug charges have on efficiency and equity? Evidence from high-income countries (2008)How does copayment for health care services affect demand, health and redistribution? A systematic review of the empirical evidence from 1990 to 2011 (2013)The role of economic evaluation in the pricing and reimbursement of medicines (1997)A nationwide study on generic medicines substitution practices of Australian community pharmacists and patient acceptance (2010)Forecasting drug utilization and expenditure in a metropolitan health region (2010)Determinants of generic drug substitution in Switzerland (2011)The Effect of Drug Co-Payments on Utilization and Cost of Pharmaceuticals in a Health Maintenance Organization (1990)Dilemmas In Regulation Of The Market For Pharmaceuticals (2003)The impact of China's retail drug price control policy on hospital expenditures: a case study in two Shandong hospitals (2005)Pharmaceutical policies: effects of cap and co-payment on rational use of medicines (2015)A comparative analysis of generics markets in five European countries (2000)Consumer Perceptions of Risk and Required Cost Savings for Generic Prescription Drugs (2000)Review of the literature on reference pricing (2000)Underuse of generic medicines in Portugal: An empirical study on the perceptions and attitudes of patients and pharmacists (2011)A review of patient perspectives on generics substitution: what are the challenges for optimal drug use (2012)Potential Clinical and Economic Impact of Switching Branded Medications to Generics (2015)A Comparison of Results of Meta-analyses of Randomized Control Trials and Recommendations of Clinical Experts (1992)Use of research to inform public policymaking (2004)Effects of continuing medical education on improving physician clinical care and patient health: A review of systematic reviews (2005)The Value of Implementation and the Value of Information: Combined and Uneven Development (2007)Ethnic Disparities in Diabetic Complications in an Insured Population (2002)Cost-Related Medication Underuse Among Chronically III Adults: the Treatments People Forgo, How Often, and Who Is at Risk (2004)Unintended Consequences of Caps on Medicare Drug Benefits (2006)On the will to ignorance in bureaucracy (2007)Competition in off-patent drug markets: Issues, regulation and evidence (2008)Pharmaceutical policies in European countries in response to the global financial crisis (2011)The Efficacy of Cognitive Behavioral Therapy: A Review of Meta-analyses (2012)Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of eating disorders (2014)Defining and understanding dyslexia: past, present and future (2020)Global Competitiveness in Pharmaceuticals: A European Perspective (2000)The role of firm characteristics in pharmaceutical product launches (2006)Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countries (2014)
this work references cited by second hop

References

  • 2011Cochrane Database of Systematic Reviews4,689 cited
  • 1991Effects of Medicaid Drug-Payment Limits on Admission to Hospitals and Nursing Homes505 cited
  • 2001When Is It Cost-effective to Change the Behavior of Health Professionals?208 cited
  • 2006Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies206 cited
  • 2004Effects of Prescription Drug User Fees on Drug and Health Services Use and on Health Status in Vulnerable Populations: A Systematic Review of the Evidence200 cited
  • 2005Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality155 cited
  • 2000Pharmaceutical Policies in OECD Countries: Reconciling Social and Industrial Goals135 cited
  • 1996Lessons from international experience in controlling pharmaceutical expenditure. I: influencing patients128 cited
  • 2006Impact of a generic substitution reform on patients’ and society's expenditure for pharmaceuticals85 cited
  • 2003A prospective multicenter study of the effect of patient education on acceptability of generic prescribing in general practice84 cited
  • 1996Fortnightly Review: Lessons from international experience in controlling pharmaceutical expenditure II: influencing doctors76 cited
  • 1996Lessons from international experience in controlling pharmaceutical expenditure III: regulating industry: Table 168 cited
  • 1991Charging for health care: Evidence on the utilisation of NHS prescribed drugs

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

64 cited
  • 2006Impact of Alternative Interventions on Changes in Generic Dispensing Rates51 cited
  • 2011Effects of health savings account-eligible plans on utilization and expenditures.49 cited
  • 2000Pharmaceutical Policies in OECD Countries49 cited
  • Cited by

    No citing works inside the corpus for this window.